In contrast, truncating loss of function mutations in STAG2 are likely selected for in human cancers because STAG2 inactivation is not an essential gene, but instead is a critical regulator of cohesin function that when subverted promotes tumorigenesis without perturbing the essential functions of the core cohesin ring. This evidence concerns the gene STAG2 and cancer.